Fund Evaluator:

Fidelity Select Biotechnology Overview

Fidelity Select Biotechnology (FBIOX) is an actively managed Sector Equity Health fund. Fidelity Investments launched the fund in 1985.

The investment seeks capital appreciation. The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.

About Fidelity Select Biotechnology (FBIOX)

There are 1 members of the management team with an average tenure of 20.73 years: Rajiv Kaul (2005). Management tenure is more important for actively managed funds than passive index funds.

The fund has 2 primary benchmarks: S&P 500 (TR) (1970) index with a weighting of 100% and MSCI US IMI/Biotechnology 25-50 GR USD index with a weighting of 100%. Fidelity Select Biotechnology has 216 securities in its portfolio. The top 10 holdings constitute 45.1% of the fund’s assets. The fund meets the SEC requirement of being classified as a nondiversified fund. The fund is not considered to have an ESG focus with its investment selection and management.

Fidelity Select Biotechnology is part of the Equity global asset class and is within the Sector Equity fund group. Fidelity Select Biotechnology has 6.9% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 91.5%. There is 6.9% allocated to foreign stock, and 0.0% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). Fidelity Select Biotechnology has 0.2% of the portfolio in cash.

Assets Under Management

The fund has $5 billion in total assets, which is above the $869 million average for the Health category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.

FBIOX Performance and Fees

The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The Fidelity Select Biotechnology expense ratio is above average compared to funds in the Health category. Fidelity Select Biotechnology has an expense ratio of 0.62%, which is 49% lower than its category average, making the fund expense ratio grade a A. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.

High portfolio turnover can translate to higher expenses and lower aftertax returns. Fidelity Select Biotechnology has a portfolio turnover rate of 45%, indicating that holds its assets around 0.0 years. By way of comparison, the average portfolio turnover is 61% for the Health category.

Recently, in the month of June 2026, Fidelity Select Biotechnology returned 13.6%, which earned it a grade of A, as the Health category had an average return of 8.4%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all funds in that category.

Fidelity Select Biotechnology has a trailing yield of 1.46%, which is above the 0.39% category average. The fund normally distributes its income annually and its capital gains semi-annually.

It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.

Fidelity Select Biotechnology Grades

Year to date, the fund has returned 20.6%, 13.0 percentage points better than the category, which translates into a grade of A. The fund has returned 71.0% over the past year (grade of A), 23.9% over the past three years (grade of A) and 8.1% per year over the past five years (grade of A) and 12.2% per year over the past 10 years (grade of A).

For more mutual fund grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.

Otherwise, for more information about Fidelity Select Biotechnology, including its riskiness, submit your email to unlock the rest of the article.